An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...
An Aussie social media influencer was rushed to hospital after she endured a severe allergic reaction to getting her lip ...
Zycubo received breakthrough therapy, fast track, rare paediatric disease and orphan drug designations from the FDA.
A significantly higher proportion of 4- to 7-year-olds with peanut allergy using the Viaskin Peanut patch were deemed ...
1hon MSN
Exclusive-US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program ...
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin ...
Grandmother decided to learn the game to get rid of the stress of her grandson's cancer treatment. However, she later made it ...
MedPage Today on MSN
Rare Childhood Disorder Gets Its First FDA Drug Approval
The FDA approved copper histidinate (Zycubo) as the first treatment for Menkes disease in pediatric patients, the agency ...
Briefly on MSN
“How Will We See the Expiry Date?”: SA Outraged by New Packaging of Choice Assorted Biscuits
South Africans are questioning the new Choice Assorted biscuit packaging after a TikTok video highlighted plastic-wrapped ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...
Align Technology explains why bridging the gap between clinical planning and emotional connection is key for treatment ...
ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback